RxDoctor Payments Data

Maria Victoria Alfaro, MD

Internal Medicine · van Nuys, CANPI 1225131535

Payments from drug & device makers

$859in general payments, 2019–2025

Across 34 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$190
  • Corcept Therapeutics$144
  • GSK$98
  • Merck$49
  • Astellas Pharma US Inc$46
  • AstraZeneca$43
  • plus $289 from 11 others

What the payments were for

  • Food & beverage$859100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$859 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$49,271
Medicare patients
93
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate15$38,289
EliquisApixaban91$29,788
SantylCollagenase Clostridium Hist.11$19,351
TriumeqAbacavir/Dolutegravir/Lamivudi12$18,510
JanuviaSitagliptin Phosphate14$12,487
JardianceEmpagliflozin14$12,356
OzempicSemaglutide11$12,059
Spiriva HandihalerTiotropium Bromide12$6,623
RhopressaNetarsudil Mesylate15$5,265
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$4,618
Divalproex Sodium83$3,751
Divalproex Sodium ErDivalproex Sodium21$2,131
Atorvastatin Calcium220$2,077
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,064
Olanzapine76$1,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$29,78891 claims
MerckJanuvia$49$12,48714 claims
Boehringer IngelheimJardiance$29$12,35614 claims
Lilly USA, LLCOlanzapine$28$1,58076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →